Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 May 2024
Molnupiravir for treating COVID-19 [ID6340]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Sipavibart for preventing COVID-19 [ID6282]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 28 May 2025
Ensitrelvir for treating COVID-19 [ID6231]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cytokine adsorption technologies for treating respiratory failure in people with COVID-19Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemicStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
FebriDx for C-reactive protein and myxovirus resistance protein A testingStatus:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Syne Covid for predicting COVID-19 outcomes MT655Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
RespiraSense (MT736)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC